Nonrandomized Comparison between Concomitant and Sequential Chemoradiotherapy with Anthracyclines in Breast Cancer

Purpose To evaluate the tolerance of concomitant administration of anthracycline-based chemotherapy (CHT) and 3-dimensional conformal radiotherapy (RT) after breast-conserving surgery. Methods and Materials Sixty-seven patients, treated with conservative surgery followed by 3-dimensional whole breast RT and concomitant CHT regimens including “Canadian modified” CEF (5-fluorouracil, epirubicin, cyclophosphamide) or AC (doxorubicin, cyclophosphamide) were evaluated for toxicity. They were compared in terms in compliance and acute toxicity with 67 patients irradiated sequentially after having received anthracyclines. Results Acute grade ≥2 skin toxicity was significantly higher in the concomitant group compared to the sequential group, although the incidence of Grade 3 desquamation showed no statistical difference (9% vs. 3%, p = 0.14). Haematological toxicity represented the main cause of treatment discontinuation, reporting higher rate of grade 3-4 leuco-neutropenia in the concomitant group (20.9% vs. 6%, p = 0.01). Mean RT duration was longer in the concomitant group (51 days vs. 45 days) owing to RT breaks. Late toxicity was acceptable. No symptomatic lung and heart events were reported. Radiological lung hyperdensity was detected in 27.7% of the patients in the concomitant group. Post-treatment left ventricular ejection fraction significantly decreased compared with baseline, but cardiac function remained within the normal range, without any difference between left or right-sided RT. Conclusions Although there was more acute grade ≥2 skin toxicity in the concomitant group, the rate of grade 3 dermatitis was lower than expected, suggesting some advantages of 3-D CRT over older techniques. Haematological toxicity exerted a significant impact on both RT and CHT delivery.

[1]  Michel Bolla,et al.  Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. , 2008, European journal of cancer.

[2]  A. Recht Phase III Trial of Concurrent or Sequential Adjuvant Chemoradiotherapy After Conservative Surgery for Early-Stage Breast Cancer: Final Results of the ARCOSEIN Trial , 2007 .

[3]  A. Neugut,et al.  Radiation therapy, cardiac risk factors, and cardiac toxicity in early-stage breast cancer patients. , 2007, International journal of radiation oncology, biology, physics.

[4]  H. Bartelink,et al.  Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. , 2007, Journal of the National Cancer Institute.

[5]  Qifeng Yang,et al.  Concurrent chemo-radiation in the conservative management of breast cancer. , 2006, International journal of radiation oncology, biology, physics.

[6]  L. Demange,et al.  A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: final results. , 2006, International journal of radiation oncology, biology, physics.

[7]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[8]  R. T. Ten Haken,et al.  Body Mass Index Predicts the Incidence of Radiation Pneumonitis in Breast Cancer Patients , 2005, Cancer journal.

[9]  H. J. Wallace Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: Updated results of a prospective randomized trial , 2005 .

[10]  J. Nortier,et al.  Acute toxicity of concurrent adjuvant radiotherapy and chemotherapy (CMF or AC) in breast cancer patients. a prospective, comparative, non-randomised study. , 2003, European journal of cancer.

[11]  J. Flickinger,et al.  Concurrent sequencing of full-dose CMF chemotherapy and radiation therapy in early breast cancer has no effect on treatment delivery. , 2003, European journal of cancer.

[12]  G. Bonadonna,et al.  Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  T. Whelan,et al.  Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Yarnold,et al.  Mixing anthracyclines and radiotherapy in early breast cancer: how safe is it? , 1996, European journal of cancer.

[15]  D. Schultz,et al.  The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. , 1996, International journal of radiation oncology, biology, physics.

[16]  T. Pajak,et al.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) , 1995, International journal of radiation oncology, biology, physics.

[17]  F. Vicini,et al.  Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. , 1991, International journal of radiation oncology, biology, physics.

[18]  K. Luk,et al.  The reverse hockey stick technique: postmastectomy radiation therapy for breast cancer patients with locally advanced tumor presentation or extensive loco-regional recurrence. , 1989, International journal of radiation oncology, biology, physics.

[19]  F. Stockdale,et al.  The effect of postoperative and primary radiation therapy on delivered dose of adjuvant Cyclophosphamide, methotrexate, and 5‐fluorouracil (CMF) chemotherapy in breast cancer , 1984, Cancer.